Skip to content

Celator Pharmaceuticals Inc: 10-Q filed 2013-05-15

What Celator Pharmaceuticals Inc reported in its quarterly report filed 2013-05-15 (fiscal Q1 2013): 31 published measures, 99 facts as tagged in accession 0001193125-13-222290.

This filing

Form
10-Q (quarterly report)
Filed
2013-05-15
Fiscal period
fiscal Q1 2013
Accession
0001193125-13-222290 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Celator Pharmaceuticals Inc filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-03-3110,671,402USD
At 2012-12-3113,438,944USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-03-316,773,497USD
At 2012-12-316,587,164USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-03-313,897,905USD
At 2012-12-316,851,780USD
At 2011-12-312,560,265USD
At 2010-12-3111,613,069USD
At 2009-12-317,429,387USD
At 2008-12-3117,239,038USD
At 2007-12-318,494,122USD
At 2006-12-3115,003,827USD
At 2005-12-3129,385,947USD
At 2004-12-31-11,070,992USD
At 2003-12-31-4,829,993USD
At 2002-12-31-847,815USD
At 2001-12-31498,307USD
At 2000-12-31204,118USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-03-318,110,389USD
At 2012-12-319,648,008USD
At 2012-03-312,355,508USD
At 2011-12-313,226,778USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,958,151USD90
1999-11-19 to 2013-03-31-114,579,366USD4882
2012-01-01 to 2012-12-31-10,908,727USD366
2012-01-01 to 2012-03-31-2,029,617USD91
2011-01-01 to 2011-12-31-14,159,754USD365
2010-01-01 to 2010-12-31-10,814,788USD365
2009-01-01 to 2009-12-31-10,022,979USD365
2008-01-01 to 2008-12-31-14,028,617USD366
2007-01-01 to 2007-12-31-16,761,805USD365
2006-01-01 to 2006-12-31-14,588,786USD365
2005-01-01 to 2005-12-31-8,913,249USD365
2004-01-01 to 2004-12-31-5,445,046USD366
2003-01-01 to 2003-12-31-3,506,027USD365
2002-01-01 to 2002-12-31-1,497,719USD365
2001-01-01 to 2001-12-31-773,668USD365
1999-11-19 to 2000-12-31-200,050USD409

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-1,263,969USD90
1999-11-19 to 2013-03-31-100,368,464USD4882
2012-01-01 to 2012-03-31-937,109USD91

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
1999-11-19 to 2013-03-317,337,998USD4882
2012-01-01 to 2012-03-3114,955USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-300,000USD90
1999-11-19 to 2013-03-31116,481,748USD4882
2012-01-01 to 2012-03-3177,356USD91

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-01-01 to 2013-03-3129,976USD90
1999-11-19 to 2013-03-31-6,912,634USD4882
2012-01-01 to 2012-03-31-9,941USD91

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
1999-11-19 to 2013-03-31-6,243,583USD4882

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-03-311,197,437USD
At 2012-12-311,245,025USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,907,877USD90
1999-11-19 to 2013-03-31-118,275,436USD4882
2012-01-01 to 2012-03-31-1,663,662USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-03-319,312,863USD
At 2012-12-3112,088,114USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-01-01 to 2013-03-3147,654USD90
1999-11-19 to 2013-03-315,936,946USD4882
2012-01-01 to 2012-03-31366,917USD91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-03-314,350,419USD
At 2012-12-313,710,240USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-03-31597,169USD
At 2012-12-31699,858USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-01-01 to 2013-03-311,651,409USD90
1999-11-19 to 2013-03-3182,069,074USD4882
2012-01-01 to 2012-03-31920,475USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-03-3113,673,160shares
At 2012-12-3113,673,160shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-03-31118,513,671USD
At 2012-12-31118,509,395USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2013-03-31-1,133,266USD
At 2012-12-31-1,133,266USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2013-03-313,897,905USD
At 2012-12-316,851,780USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2013-03-312,257,125USD
At 2012-12-312,257,125USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2013-03-311,059,688USD
At 2012-12-311,012,100USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-03-31161,102USD
At 2012-12-31105,805USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-03-311,937,866USD
At 2012-12-311,194,998USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,958,151USD90
1999-11-19 to 2013-03-31-119,347,096USD4882
2012-01-01 to 2012-03-31-2,029,617USD91

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-2,958,151USD90
1999-11-19 to 2013-03-31-115,712,632USD4882
2012-01-01 to 2012-03-31-2,029,617USD91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-01-01 to 2013-03-311,348,999USD90
1999-11-19 to 2013-03-3138,549,719USD4882
2012-01-01 to 2012-03-31778,350USD91

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2013-01-01 to 2013-03-3138,164USD90
1999-11-19 to 2013-03-311,081,980USD4882

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
1999-11-19 to 2013-03-318,515,281USD4882
2012-01-01 to 2012-03-31240USD91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-03-31-101,786USD90
1999-11-19 to 2013-03-31598,075USD4882
2012-01-01 to 2012-03-31-312,858USD91

Inspect the source

Entity
Celator Pharmaceuticals Inc / CIK 0001327467
Captured
SEC response SHA-256
7d372507a0b1143a77b3789a7b6b8fde9a142f2ac640aa32396c294d5de3edc7

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001327467.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))